Edition:
United States

AC Immune SA (ACIU.OQ)

ACIU.OQ on NASDAQ Stock Exchange Global Market

12.70USD
15 Dec 2017
Change (% chg)

$0.40 (+3.25%)
Prev Close
$12.30
Open
$12.33
Day's High
$12.90
Day's Low
$12.33
Volume
18,226
Avg. Vol
26,820
52-wk High
$14.78
52-wk Low
$6.24

Summary

Name Age Since Current Position

Martin Velasco

Chairman of the Board of Directors

Andrea Pfeifer

59 2003 Chief Executive Officer

Joerg Hornstein

2017 Chief Financial Officer

Andreas Muhs

2005 Chief Scientific Officer

Friedrich von Bohlen und Halbach

2015 Member of Board of Director

Peter Bollmann

2015 Member of Board of Director

Thomas Graney

52 2016 Member of Board of Director

Detlev Riesner

73 Member of the Board of Directors

Biographies

Name Description

Martin Velasco

Mr. Martin Velasco serves as Chairman of the Board of Directors of AC Immune Ltd. He is an entrepreneur and Business Angel with experience in the IT medical and biotech areas. He serves on the board of directors or advisory board of several other high-tech companies including: as Founder, Chairman and Chief Executive Officer of Anecova, as Founder and Chairman of Sumerian, as Chairman of the Supervisory Board of Cocomore, as Board Member of Aridhia, and as Board Member of Aleva Neurotherapeutics. He is also the Founder and Chairman of Infantia Foundation, a philanthropic organization aiding children in the developing world. He is a member of the Board of BlueOrchard, the leading private microfinance investment advisory company, member of the Strategic Advisory Board of the EPFL, Vice President of the Board of the Foundation EPFL+ and Vice Chairman of the European Tech Tour Association.

Andrea Pfeifer

Prof. Dr. Andrea Pfeifer, Ph.D., has been Chief Executive Officer of AC Immune Ltd since 2003. Prior to AC Immune she was head of Nestle's Global Research in Lausanne, Switzerland and managed a group of more than 600 people. While at Nestle, she led the scientific development of the first Functional Food, LC1, and one of the first Cosmoceutical products in a joint venture with L’Oreal, Inneov Fermete. She also co-founded the Nestle Venture Capital Fund, a Life Sciences corporate venture fund. She serves as chairwoman of the Biotechmedinvest AG Investment Fund, Basel and AB2Bio, Lausanne and is member of the Supervisory Board of Symrise AG, Holzminden. Prof. Pfeifer is a member of the CEOi Initiative on Alzheimer’s Disease. She was recognized in 2009 as Technology Pioneer by the WEF and Swiss Entrepreneur of the Year by Ernst&Young. She holds a Ph.D. in Toxicology, Cancer Research from the University of Wuerzburg, Germany and continued with post-doctoral work in Molecular Carcinogenesis at the National Institutes of Health, Human Carcinogenesis Branch, in Bethesda, USA. She is a registered Toxicologist and Pharmacist, received her habilitation from the University of Lausanne, Switzerland and is an honorary professor at the Ecole Polytechnique Federale de Lausanne, Switzerland.

Joerg Hornstein

Andreas Muhs

Friedrich von Bohlen und Halbach

Mr. Friedrich von Bohlen und Halbach is Member of Board of Director at AC Immune Ltd October 2015. He is co-founder and managing director of dievini Hopp BioTech holding GmbH & Co. KG. He brings extensive industry experience from Fresenius AG, FAG Kugelfischer, and WASAG-Chemie AG, founded LION bioscience AG in 1997 (now SYGNIS Pharma AG) and served as the companys CEO. Dr. von Bohlen is a board member of various companies of the dievini portfolio and Chairman of Apogenix AG, CureVac AG and Novaliq GmbH. He holds a PhD in Neurobiology from the Swiss Federal Institute of Technology in Zurich, Switzerland.

Peter Bollmann

Mr. Peter Bollmann is Member of Board of Director at AC Immune Ltd since December 2015. He has extensive management and finance experience in Switzerland and abroad as CEO, CFO and member of the board. His broad industry experience embraces biotechnology and medical technology firms including previous Board positions with Cytos Biotechnology and Prionics.

Thomas Graney

Detlev Riesner

Prof. Dr. Detlev H. Riesner, Ph.D., is Member of the Board of Directors of AC Immune Ltd. He held the Chair of Biophysics at the Heinrich-Heine-University in Duesseldorf, Germany from 1980 to 2007. He has also held the positions of Dean of the Science Faculty and Vice-President of Research. In 2007 he became member of the university’s Board of Trustees. He worked as a research fellow at Princeton University and held a guest professorship at the department of Neurology at the University of California, San Francisco. Prof. Dr. Riesner is a co-founder of Qiagen N.V., Netherlands, was a member and from 1999 to 2014 chairman of the Supervisory Board. He was also a member of the supervisory boards of NewLab Bioquality AG, Erkrath, Direvo AG, Köln, and Alantos AG, Heidelberg. Prof. Dr. Riesner was a member of the scientific advisory boards of the Friedrich-Loeffler-Institut, Isle of Riems, and PrioNet and APRI, both Canada. He received the Max-Planck Forschungspreis for International Co-operation and the Bundesverdienstkreuz 1. Klasse from the Bundespresident of Germany.